Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefprozil Anhydrous, (E)-. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.98 |
| ▸ | MEN1 | O00255 | 5/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.75 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | ESR1 | P03372 | 1/20 | 0.75 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.75 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefprozil Anhydrous, (E)- SCHEMBL9177544 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil Anhydrous, (E)- SCHEMBL18814837 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil Anhydrous, (E)- SCHEMBL14108301 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil SCHEMBL37024 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil Anhydrous, (E)- SCHEMBL5191958 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil Anhydrous, (E)- SCHEMBL10801275 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil Anhydrous, (E)- SCHEMBL7586258 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil Anhydrous, (E)- SCHEMBL2901170 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil Anhydrous, (E)- SCHEMBL14064854 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 | |
| Cefprozil Anhydrous, (E)- SCHEMBL37023 | 1.00 | PTGS2 (1.00) | PTGS2DRD2DRD3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813235-B2 | Guanfacine as an anti-virulence agent | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20200297669-A1 | GUANFACINE AS AN ANTI-VIRULENCE AGENT | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME CORP. | 2014-09-18 | — | — | US | disclosed |
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME CORP. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | PTGS2 3396/4885DRD2 2436/4885DRD3 2477/4885 |
| US-11813235-B2 | Guanfacine as an anti-virulence agent | GMPS, GUCY1A2, GUCY1A1 | PTGS2 953/4885DRD2 2373/4885DRD3 2595/4885 |
| US-20200297669-A1 | GUANFACINE AS AN ANTI-VIRULENCE AGENT | GMPS, GUCY1A2, GUCY1A1 | PTGS2 953/4885DRD2 2373/4885DRD3 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.